Immix Biopharma, Inc. SEC filings IMMX
Immix Biopharma, Inc. has 244 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| FWP | Free writing prospectus | Sep 29, 2026 | — |
| 424B5 | Prospectus supplement | Sep 29, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 424B5 | Prospectus supplement | May 21, 2026 | — |
| FWP | Free writing prospectus | May 21, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 6, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | Apr 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 30, 2026 | Mar 30, 2026 |
| 10-K/A | Amended annual report | Mar 27, 2026 | Dec 31, 2025 |
| S-8 | Employee stock plan registration | Mar 25, 2026 | — |
| 8-K |
Current report
Material agreement
|
Mar 25, 2026 | Mar 25, 2026 |
| 424B5 | Prospectus supplement | Mar 25, 2026 | — |
| 10-K | Annual report | Mar 25, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Jan 22, 2026 | — |
| CORRESP | Letter to the SEC | Jan 16, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2026 | — |
| S-3 | Shelf registration | Jan 9, 2026 | — |
| 8-K |
Current report
Material agreement
|
Dec 8, 2025 | Dec 7, 2025 |
| 424B5 | Prospectus supplement | Dec 8, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2025 | Dec 7, 2025 |
| FWP | Free writing prospectus | Dec 8, 2025 | — |
| EFFECT | Filing | Dec 1, 2025 | — |
| CORRESP | Letter to the SEC | Nov 26, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 26, 2025 | Nov 26, 2025 |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| S-3 | Shelf registration | Oct 6, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Sep 8, 2025 | Sep 5, 2025 |
| 10-Q | Quarterly report | Aug 8, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2025 | Jun 20, 2025 |
| 424B5 | Prospectus supplement | Jun 3, 2025 | — |
| 8-K |
Current report
Material agreement
|
Jun 3, 2025 | Jun 3, 2025 |
| ARS | Annual report to shareholders | May 19, 2025 | Dec 31, 2024 |
| 10-Q/A | Amended quarterly report | May 19, 2025 | Mar 31, 2025 |
| DEFA14A | Additional proxy material | May 19, 2025 | — |
| 10-K/A | Amended annual report | May 19, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| DEFA14A | Additional proxy material | May 5, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Apr 29, 2025 |
| 10-K | Annual report | Mar 25, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Jul 26, 2024 | Jul 25, 2024 |
| 8-K |
Current report
Auditor change
|
Jul 22, 2024 | Jul 17, 2024 |
| S-8 | Employee stock plan registration | Jul 22, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 14, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | May 21, 2024 | — |
| 8-K |
Current report
Unregistered share sale, Other events
|
May 20, 2024 | May 20, 2024 |
| D | Filing | May 20, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 30, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| 10-K | Annual report | Mar 29, 2024 | Dec 31, 2023 |
| S-8 | Employee stock plan registration | Feb 20, 2024 | — |
| 424B5 | Prospectus supplement | Feb 7, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Feb 6, 2024 | Feb 6, 2024 |
| 424B5 | Prospectus supplement | Feb 5, 2024 | — |
| 8-K |
Current report
Other events
|
Feb 5, 2024 | Feb 5, 2024 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| EFFECT | Filing | Sep 28, 2023 | — |
| CORRESP | Letter to the SEC | Sep 26, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2023 | — |
| S-3 | Shelf registration | Sep 25, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Aug 22, 2023 | Aug 22, 2023 |
| 10-Q | Quarterly report | Aug 11, 2023 | Jun 30, 2023 |
| 424B5 | Prospectus supplement | Jul 14, 2023 | — |
| 8-K |
Current report
Material agreement
|
Jul 14, 2023 | Jul 14, 2023 |
| S-8 | Employee stock plan registration | Jun 13, 2023 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2023 | Jun 7, 2023 |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| ARS | Annual report to shareholders | Apr 25, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 25, 2023 | Apr 25, 2023 |
| 10-K | Annual report | Mar 27, 2023 | Dec 31, 2022 |
| 424B5 | Prospectus supplement | Mar 22, 2023 | — |
| 8-K |
Current report
Material agreement
|
Mar 22, 2023 | Mar 22, 2023 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 18, 2023 | Jan 12, 2023 |
| EFFECT | Filing | Jan 11, 2023 | — |
| CORRESP | Letter to the SEC | Jan 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2023 | — |
| S-3 | Shelf registration | Jan 3, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 16, 2022 | Dec 16, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 14, 2022 | Dec 8, 2022 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| RW | Filing | Jul 19, 2022 | — |
| RW WD | Filing | Jun 30, 2022 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 8, 2022 |
| FWP | Free writing prospectus | May 27, 2022 | — |
| S-1 | Registration statement | May 27, 2022 | — |
| DRS | Filing | May 24, 2022 | — |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Apr 25, 2022 |
| 10-K | Annual report | Mar 28, 2022 | Dec 31, 2021 |
| S-8 | Employee stock plan registration | Jan 25, 2022 | — |
| 8-K |
Current report
Other events
|
Jan 19, 2022 | Jan 19, 2022 |
| 8-K |
Current report
Other events
|
Jan 12, 2022 | Jan 12, 2022 |
| 8-K |
Current report
Other events
|
Jan 3, 2022 | Jan 3, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Dec 20, 2021 | Dec 20, 2021 |
| 424B4 | Prospectus | Dec 17, 2021 | — |
| SEC STAFF LETTER | Filing | Dec 15, 2021 | — |
| EFFECT | Filing | Dec 15, 2021 | — |
| CERT | Filing | Dec 14, 2021 | — |
| CORRESP | Letter to the SEC | Dec 13, 2021 | — |
| CORRESP | Letter to the SEC | Dec 13, 2021 | — |
| 8-A12B | Filing | Dec 13, 2021 | — |
| FWP | Free writing prospectus | Dec 1, 2021 | — |
| S-1/A | Amended registration statement | Nov 4, 2021 | — |
| S-1/A | Amended registration statement | Oct 28, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 19, 2021 | — |
| S-1/A | Amended registration statement | Oct 15, 2021 | — |
| CORRESP | Letter to the SEC | Oct 15, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 13, 2021 | — |
| CORRESP | Letter to the SEC | Oct 6, 2021 | — |
| S-1/A | Amended registration statement | Oct 6, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2021 | — |
| S-1 | Registration statement | Sep 17, 2021 | — |
| CORRESP | Letter to the SEC | Sep 16, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2021 | — |
| DRSLTR | Filing | Jul 20, 2021 | — |
| DRS | Filing | Jul 20, 2021 | — |
Showing 132 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.